Market News Archive
Stay updated with the latest announcements
ACMELAB: Q1 Financials
(Q1 Un-audited): EPS was Tk. 2.61 for July-September 2024 as against Tk. 3.11 for July-September 2023; NOCFPS was Tk. 6.44 for July-September 2024 as against Tk. 2.93 for July-September 2023. NAV per share was Tk. 121.02 as on September 30, 2024 and Tk. 118.39 as on June 30, 2024.
METROSPIN: Q1 Financials
(Q1 Un-audited): EPS was Tk. (0.50) for July-September 2024 as against Tk. (0.73) for July-September 2023; NOCFPS was Tk. 0.26 for July-September 2024 as against Tk. 0.08 for July-September 2023. NAV per share was Tk. 6.32 as on September 30, 2024 and Tk. 7.07 as on June 30, 2024. Reasons for deviation in NOCFPS: NOCFPS increased due to decrease payment against cost and others expenses in comparison to the previous period of previous year.
ADVENT: Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.16 for July-September 2024 as against Tk. 0.35 for July-September 2023; NOCFPS was Tk. 0.19 for July-September 2024 as against Tk. 0.45 for July-September 2023. NAV per share was Tk. 15.94 as on September 30, 2024 and Tk. 15.78 as on June 30, 2024.
RAHIMAFOOD: Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.20 for July-September 2024 as against Tk. 0.26 for July-September 2023; NOCFPS was Tk. 0.64 for July-September 2024 as against Tk. 1.16 for July-September 2023. NAV per share was Tk. 10.58 as on September 30, 2024 and Tk. 10.58 as on June 30, 2024.
HWAWELLTEX: Q1 Financials
(Q1 Un-audited): EPS was Tk. 1.17 for July-September 2024 as against Tk. 1.38 for July-September 2023; NOCFPS was Tk. 1.79 for July-September 2024 as against Tk. 2.71 for July-September 2023. NAV per share was Tk. 39.68 as on September 30, 2024 and Tk. 39.19 as on September 30, 2023.
BBS: Q1 Financials
(Q1 Un-audited): EPS was Tk. (0.27) for July-September 2024 as against Tk. (0.19) for July-September 2023; NOCFPS was Tk. 0.24 for July-September 2024 as against Tk. 0.42 for July-September 2023. NAV per share was Tk. 12.00 as on September 30, 2024 and Tk. 12.92 as on June 30, 2024.
BXPHARMA: Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 3.77 for July-September 2024 as against Tk. 3.48 for July-September 2023; Consolidated NOCFPS was Tk. 3.80 for July-September 2024 as against Tk. 6.07 for July-September 2023. Consolidated NAV per share was Tk. 111.25 as on September 30, 2024 and Tk. 101.40 as on September 30, 2023.
PHARMAID: Q1 Financials
(Q1 Un-audited): EPS was Tk. 5.66 for July-September 2024 as against Tk. 3.68 for July-September 2023; NOCFPS was Tk. 0.43 for July-September 2024 as against Tk. 3.29 for July-September 2023. NAV per share was Tk. 115.52 as on September 30, 2024 and Tk. 109.89 as on June 30, 2024.
CVOPRL: Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.92 for July-September 2024 as against Tk. 1.10 for July-September 2023; NOCFPS was Tk. 0.48 for July-September 2024 as against Tk. 3.57 for July-September 2023. NAV per share was Tk. 11.22 as on September 30, 2024 and Tk. 10.31 as on June 30, 2024. NOCFPS decreased due to increase in payment to suppliers than collection from customers.
SPCL: Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 0.36 for July-September 2024 as against Tk. 2.24 for July-September 2023; Consolidated NOCFPS was Tk. (0.15) for July-September 2024 as against Tk. 1.80 for July-September 2023. Consolidated NAV per share was Tk. 38.28 as on September 30, 2024 and Tk. 37.92 as on June 30, 2024. Reason for Significant Deviation: (cont.1)
QUEENSOUTH: Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.08 for July-September 2024 as against Tk. 0.07 for July-September 2023; NOCFPS was Tk. (0.23) for July-September 2024 as against Tk. (0.97) for July-September 2023. NAV per share was Tk. 15.80 as on September 30, 2024 and Tk. 15.71 as on June 30, 2024.
DOREENPWR: Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 1.48 for July-September 2024 as against Tk. 1.80 for July-September 2023; Consolidated NOCFPS was Tk. (15.88) for July-September 2024 as against Tk. (6.07) for July-September 2023. Consolidated NAV per share with revaluation was Tk. 51.05 as on September 30, 2024 and Tk. 49.57 as on June 30, 2024. Reasons for deviation in EPS and NOCFPS: (cont.)
ARGONDENIM: Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.45 for July-September 2024 as against Tk. 0.29 for July-September 2023; NOCFPS was Tk. 1.18 for July-September 2024 as against Tk. 3.01 for July-September 2023. NAV per share was Tk. 24.34 as on September 30, 2024 and Tk. 23.89 as on June 30, 2024.
INTECH: Q1 Financials
(Q1 Un-audited): EPS was Tk. (0.08) for July-September 2024 as against Tk. (0.15) for July-September 2023; NOCFPS was Tk. (0.02) for July-September 2024 as against Tk. (0.05) for July-September 2023. NAV per share was Tk. (0.13) as on September 30, 2024 and Tk. (0.05) as on June 30, 2024.
UPGDCL: Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 7.13 for July-September 2024 as against Tk. 3.12 for July-September 2023; Consolidated NOCFPS was Tk. 1.85 July-September 2024 as against Tk. 5.19 for July-September 2023. Consolidated NAV per share was Tk. 66.36 as on September 30, 2024 and Tk. 59.23 as on June 30, 2024. Reasons for deviation: During the period, a rise in bulk tariffs for electricity and stable foreign exchange rates, compared to the same period of last year, (cont.)
PHARMAID: Regarding New Machinery Investment & Land Revaluation for Q2 Accounts
The company has informed that the Board, in order to meet the rising market demand, has decided to invest Company's own fund to import 01(one) complete line of brand new machine within June 2025 for manufacturing ampoules and expanding production. The Board has also approved the revaluation amount of the Company's existing factory land as per the land valuation report. dated 26-10-2024. by Fames & R Chartered Accountants. (cont.)
COPPERTECH: Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.02 for July-September 2024 as against Tk. 0.11 for July-September 2023; NOCFPS was Tk. 0.17 for July-September 2024 as against Tk. 0.75 for July-September 2023. NAV per share was Tk. 13.90 as on September 30, 2024 and Tk. 13.89 as on June 30, 2024. Reasons for deviations in EPS and NOCFPS: The country experienced an uncertain scenario at the beginning of this quarter that lasted for long period, resulting in operational disruption and substantial drop in revenue. (cont.)
BEXIMCO: Q1 Financials
(Q1 Un-audited): EPS was Tk. (1.26) for July-September 2024 as against Tk. (0.79) for July-September 2023; NOCFPS was Tk. 10.96 July-September 2024 as against Tk. (2.69) for July-September 2023. NAV per share was Tk. 89.44 as on September 30, 2024 and Tk. 94.21 as on September 30, 2023.
GENEXIL: Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 0.69 for July-September 2024 as against Tk. 0.82 for July-September 2023; Consolidated NOCFPS was Tk. 0.91 for July-September 2024 as against Tk. 1.69 for July-September 2023. Consolidated NAV per share was Tk. 21.23 as on September 30, 2024 and Tk. 20.38 as on June 30, 2024.
DESCO: Q1 Financials
(Q1 Un-audited): EPS was Tk. (0.81) for July-September 2024 as against Tk. (3.82) for July-September 2023; NOCFPS was Tk. 2.15 for July-September 2024 as against Tk. 2.94 for July-September 2023. NAV per share was Tk. 37.12 as on September 30, 2024 and Tk. 37.92 as on June 30, 2024. EPS has been increased due to increase in distribution revenue.